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ural history model to project clinical and/or economic outcomes. METHODS: The
subset of stage I-III colon cancer patients who will experience recurrence face a
constant rate rd of transition from undetectable to theoretically detectable recur-
rence during a given interval. These same patients face a constant rate ru of tran-
sition from resectable (i.e. potentially curable) to unresectable metastatic disease
with a minimum interval xdu between the point of detectability and the point of
unresectability. A third constant rate parameter rs will determine when, on aver-
age, individuals develop recurrence-related symptoms prompting them to seek
medical advice before the next scheduled evaluation. The mean point of symptom
development will follow the point at which a recurrence becomes detectable by a
span of at least xds. However, a normally distributed error term Eds will mean that,
for a given simulated patient, symptoms may initiate before or after the patient
reaches unresectability.RESULTS:A best-fitting set of these natural history param-
eters can be selected by calibrating to targets of time-to-detection of recurrence,
time-to-death, and proportion of patients who present with recurrence-related
symptoms prior to scheduled assessments. CONCLUSIONS: The data sources for
these targets can be existing experimental, observational, or registry data where
follow-up schedule and compliance levels are known.
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OBJECTIVES: Recent work on differential discounting of cost and health effects has
reached a degree of consensus in a previously strongly divided debate. Put simply,
it holds that the discount rate applied to health effects should equal the discount
rate for costs, less the growth rate of either the cost-effectiveness threshold or the
consumption value of health, depending on the objectives of the health system.
Assuming positive growth in the threshold or the value of health, this implies the
cost-effectiveness of preventative interventions improves relative to the situation
under equal discounting. METHODS: We show how recent analyses of differential
discounting implicitly assume healthcare funds to be completely fungible over
time. This assumption is difficult to justify in the context of publically funded
healthcare systems that exhaust budgets annually. Assuming funds are not fungi-
ble results in alternative differential discount rates: in this case, the discount rate
on costs should be adjusted upwards by either the growth rate of the threshold or
the consumption value of health. RESULTS: Under these discount rates, interven-
tions that impose costs in future periods become more cost-effective relative to the
situation under equal discounting, rather than those which yield health gains in
the future. Indeed, the cost-effectiveness of preventative interventions that reduce
future healthcare costs will deteriorate under such alternative differential dis-
counting. Consequently, interventions’ cost-effectiveness may differ greatly be-
tween the two differential discounting schemes. CONCLUSION: Cost-effectiveness
estimates can be highly sensitive to discounting; therefore the theory underpin-
ning discount rates needs to be robust. This analysis shows that the current un-
derstanding of differential discounting needs to be re-examined. CEA authorities in
countries currently employing differential discounting such as Belgium and The
Netherlands and those contemplating it such as England and Wales should con-
sider these issues carefully.
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OBJECTIVES: Existing cost-effectiveness analyses (CEAs) of Human Papillomavirus
(HPV) vaccination assume cervical screening remains unchanged. However, cur-
rent screening intensities are unlikely to be cost-effective due to the likely reduc-
tion in disease incidence in vaccinated women. Therefore, reductions in screening
intensity are probable. The cost-effectiveness attributable to vaccination varies
with screening intensity. The assumption of unaltered screening leads to an un-
derestimation of vaccine cost-effectiveness relative to when screening intensity is
reduced. Furthermore, failure to consider other screening intensities yields an in-
complete efficient frontier in the cost-effectiveness plane. This can lead to an
incorrect estimate of the price at which vaccination becomes marginally cost-
effective for a given cost-effectiveness threshold. METHODS: We review cost-ef-
fectiveness estimates for a wide range of screening only and vaccination plus
screening strategies from a model used to estimate vaccine cost-effectiveness in
the The Netherlands. We indicate what comparison was used to estimate vaccine
cost-effectiveness in previous studies, show what comparisons would be more
appropriate and explain how these differ. RESULTS: We then show why the cost-
effectiveness of adding vaccination to a given screening strategy is not the appro-
priate basis to determine if the vaccine is cost-effective or the threshold price.
Rather, both should be determined by the ICER between the most costly efficient
screening only strategy and the least costly vaccination plus screening strategy,
even where this least costly vaccination plus screening strategy is not the optimal
strategy for a given threshold. CONCLUSIONS: CEAs of HPV vaccination may no
longer be policy or research priorities following widespread reimbursement and
precipitous price reductions. However, the methodological issues raised here are
pertinent to both any future CEA of an enhanced vaccine with protection against
more HPV types and more generally to cases in which the cost-effectiveness of
complementary interventions are not independent.
PRM58
METHODOLOGICAL REVIEWS OF ECONOMIC EVALUATIONS IN HEALTH CARE:
ARE THEY USEFUL?
Hutter MF, Antonanzas F
University of La Rioja, Logrono, La Rioja, Spain
INTRODUCTION AND OBJECTIVES: The increasing amount of economic evalua-
tions in health technologies published during the last decades have generated the
concern about their methodological features. The aim of this study is, firstly, to
explore methodological reviews and to detect their main research topics and, sec-
ondly, to appraise their usefulness for economic evaluation practice. METHODS:
We performed systematic searches in electronic databases (Scopus, Medline and
Pubmed) of methodological reviews published in English, period 1990- 2010. We
selected those articles whose main purpose was to review and assess the applied
methodology. Then we classified data according to study objectives, period of the
review, number of reviewed studies, methodological items assessed and their
main conclusions. Additionally, we checked how generalizability issues were con-
sidered in the reviews. RESULTS: A total of 58 methodological reviews were iden-
tified, 42 were published during the period 1990 - 2001 and 16 during 2002-10. Items
most frequently assessed (by 70% of the reviews) were: perspective, uncertainty
and discounting. The type of intervention and disease, funding sources, country in
which the evaluation took place, type of journal and author’s characteristics were
also described in the literature. Generalizability issues were only checked in 14
studies, mainly by those published after 2000. CONCLUSIONS: there is an increas-
ing activity of reviewing economic evaluation studies aiming to analyse the appli-
cation of methodological principles and to offer summaries of papers classified by
either diseases or health technologies. These reviews are useful to detect literature
trends, targets of the studies and possible deficiencies in the implementation of the
methods to specific health interventions.
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OBJECTIVES: To demonstrate a novel way of deriving the incremental cost-effec-
tiveness ratio (ICER) and associated 95% confidence interval (CI) from the cost-
effectiveness acceptability curve (CEAC) generated from a family of regressions on
net monetary benefit (NMB). METHODS: Definitions and mathematical properties
of the ICER, NMB, and CEAC are explored to construct a technique for deriving 95%
CIs around the ICER estimated from the CEAC. RESULTS: CEA uses the ICER, a
measure with statistical issues that preclude easy derivation of confidence inter-
vals. NMB is defined for any willingness-to-pay (WTP) value as: NMB  (effective-
ness X WTP) – cost. Because NMB is statistically well-behaved, regression analysis
can estimate incremental net monetary benefit (INMB) as the parameter estimate
associated with treatment. INMB  (delta effectiveness X WTP) – delta cost. The
CEAC is generated from a family of these regressions where the unique members of
the family are identified by unique levels of WTP used to calculate NMB. The ICER
is the point on the CEAC where the probability of being cost-effective is 50%, be-
cause at that point INMB is zero and WTP equals delta cost/delta effectiveness; i.e.,
the ICER. That point on the CEAC can be identified numerically by simultaneously
solving the two equations for INMB from the two regressions that flank estimated
INMB of zero. Knowing estimated INMB and the WTP we have two equations and
two unknowns, and we solve for delta effectiveness and delta cost. We use a similar
procedure on the 95% confidence intervals for two estimated INMBs to find the 95%
CI for the ICER. CONCLUSIONS: In the case where we estimate the ICER from a
family of regressions on NMB to construct the CEAC we can also find the 95% CI of
the ICER.
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OBJECTIVES: In the absence of increasing budgets, new therapies and resource
constraints have necessitated value trade-offs across tumor types and products.
Traditional metrics such as median overall survival (OS) may not fully demonstrate
the value of individual products in these comparisons. To highlight this, we as-
sessed the value of different innovative cancer drugs relative to their clinical trial
comparator using a variety of OS metrics. METHODS: We selected novel oncology
products used in the treatment of metastatic disease with documented overall
survival benefit over comparator at the time of launch. The selected products were:
bevacizumab (colorectal cancer, non squamous non-small cell lung cancer),
sunitinib (renal cell carcinoma), sorafenib (hepatocellular carcinoma), lenalido-
mide (multiple myeloma), ipilimumab (melanoma), trastuzumab (breast cancer).
Key survival metrics including median OS, mean OS, and landmark survival rates
from each analogue’s pivotal trials were used to assess the relative value of each
analogue. RESULTS: The relative value for each analogue differs depending on the
survival metric used, suggesting that median OS does not fully capture the value of
oncology agents. For example, lenalidomide’s relative value is the highest in terms
of median OS improvement; however its relative value is diminished when looking
at mean OS. Ipilimumab, conversely, shows the highest value in terms of mean OS
(attributing benefit to a proportion of patients achieving prolonged survival bene-
fit). Furthermore, sorafenib (HCC) and ipilimumab (melanoma) demonstrate the
highest relative value when evaluating 1 year survival improvement.
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